Los Angeles hospital covid-19 recommendations patient Los Angeles

Eli Lilly pauses COVID-19 antibody drug trial over potential safety concerns

Reading now: 436
www.fox29.com

LOS ANGELES - Eli Lilly and Company said on Tuesday that it has delayed enrollment in clinical trials of its antibody treatment for COVID-19 to “ensure the safety of the patients participating in this study” due to a potential safety concern. “Safety is of the utmost importance to Lilly.

We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” a company spokesperson wrote in an email.

Read more on fox29.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA